Auris shares are crushed as tinnitus drug fails PhIII test
Shares of Auris Medical $EARS zoomed up 40% yesterday and then came crashing down to the ground Thursday morning after the Swiss biotech reported that its lead drug for tinnitus failed to hit its co-primary endpoints in a pivotal Phase III study.
Instead of planning a regulatory filing, Auris will now have to start picking up the pieces from a study that failed to differentiate its drug from a placebo in eliminating the severe phantom sounds that afflict patients with tinnitus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.